Trial · NCT05168813
Results by group912
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 912
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Part A: Number of Participants With a First Occurrence of CDC-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1) | Part A (Open-label): Study Group 1, Analysis Group 1 (AG1) | 76 | Participants | ||
Part A: Number of Participants With a First Occurrence of CDC-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1) | Part A (Open-label): Study Group 2, Analysis Group 2-1 (AG2-1) | 151 | Participants | ||
Part A: Number of Participants With a First Occurrence of COVE-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1 | Part A (Open-label): Study Group 1, Analysis Group 1 (AG1) | 30 | Participants | ||
Part A: Number of Participants With a First Occurrence of COVE-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1 | Part A (Open-label): Study Group 2, Analysis Group 2-1 (AG2-1) | 40 | Participants | ||
Part A: Number of Participants With a First Occurrence of COVE-based Severe COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1) | Part A (Open-label): Study Group 1, Analysis Group 1 (AG1) | 5 | Participants | ||
Part A: Number of Participants With a First Occurrence of COVE-based Severe COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Between Analysis Group 1 (AG1) and Analysis Group 2-1 (AG2-1) | Part A (Open-label): Study Group 2, Analysis Group 2-1 (AG2-1) | 4 | Participants | ||
Part B: Number of Participants With a First Occurrence of CDC-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Boost Groups | Part B (Blinded): mRNA-1273 at Month 6 | 151 | Participants | ||
Part B: Number of Participants With a First Occurrence of CDC-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Boost Groups | Part B (Blinded): mRNA-1273.222 at Month 6 | 142 | Participants | ||
Part B: Number of Participants With a First Occurrence of COVE-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Boost Group | Part B (Blinded): mRNA-1273 at Month 6 | 8 | Participants | ||
Part B: Number of Participants With a First Occurrence of COVE-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Boost Group | Part B (Blinded): mRNA-1273.222 at Month 6 | 7 | Participants | ||
Part B: Number of Participants With a First Occurrence of COVE-based Severe COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Groups | Part B (Blinded): mRNA-1273 at Month 6 | 1 | Participants | ||
Part B: Number of Participants With a First Occurrence of COVE-based Severe COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Between Month 6 Monovalent and Bivalent Groups | Part B (Blinded): mRNA-1273.222 at Month 6 | 0 | Participants | ||
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 1 | Any Reacto After Month 0 Vaccination / Grade 0 | 320 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open Label): Study Group 2 | Any Reacto After Month 0 Vaccination / Grade 0 | 428 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 3 | Any Reacto After Month 0 Vaccination / Grade 0 | 68 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 4 | Any Reacto After Month 0 Vaccination / Grade 0 | 82 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 1 | Any Reacto After Month 0 Vaccination / Grade 1 | 158 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open Label): Study Group 2 | Any Reacto After Month 0 Vaccination / Grade 1 | 167 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 3 | Any Reacto After Month 0 Vaccination / Grade 1 | 19 | Participants | |
| Part A: Number of Participants With Solicited Adverse Events in the Safety Subset | Part A (Open-label): Study Group 4 | Any Reacto After Month 0 Vaccination / Grade 1 | 37 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05168813/results